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After delivery, our center provides a letter detailing the initial management protocol for all infants with a known risk factor (usually a positive family history) for an inborn error of metabolism that may present in early infancy. In the case of mediumchain acyl-CoA dehydrogenase deficiency, we provide a letter to the family that contains details of the diagnosis and suggestions for initial management. We ask the delivery hospital to send a newborn screen to the state laboratory immediately after birth and again at the standard time (36-48 h after birth). We provide our contact information and ask the outside provider to call us to inform of us of the birth and discuss the infant's condition. Once we are notified of the birth, we arrange to have the newborn screening results expedited. In Pennsylvania, the state laboratory can provide rapid genetic analysis for the ACADM c.A985G and c.T199C mutations. Using this strategy, if a family carries one of these common mutations, we can provide both biochemical and genetic confirmation of a diagnosis by the second day of life.
As with acylcarnitine profile analysis of umbilical-cord samples, very early blood acylcarnitine profile norms are not as well established as those for traditionally timed samples. The idea of using the sequential ratio analysis is an intriguing way to overcome this limitation. We have not used this technique at our center because we have access to rapid mutation testing for the specific mutations that have presented at an early age in our population.
Genetic confirmation of the diagnosis is greatly appreciated by the families we have managed and meets two additional goals of genetic clinical care: offering emotional reassurance of a definitive diagnosis and providing tools for future family planning. Ideally, in the future, rapid genotyping in conjunction with biochemical testing (rather than targeted mutation or acylcarnitine ratio analysis alone) using an early newborn screen blood spot will become available. Complete genotyping would provide families who harbor known, clinically significant ACADM mutations with a rapid answer as to whether their newborn is affected with the disease.
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